Crossmark

Optimized Chitosan–Lecithin Nanocarriers for Nose-to-Brain Delivery of Dalfampridine in Multiple Sclerosis: Box–Behnken Design Optimization, and Toxicity Evaluation

Crossref DOI link: https://doi.org/10.1007/s12247-026-10573-3

Published Online: 2026-04-12

Published Print: 2026-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Therassama, Jaghatha

Edward, Justus Oliver Jaslin

Arumugam, Somasundaram

Pazhani, Pavazhaviji

Dharmian, Jose Prakash
License Information

Text and Data Mining valid from 2026-04-12

Version of Record valid from 2026-04-12
More Information

Article History

Received: 8 November 2025

Accepted: 5 March 2026

First Online: 12 April 2026

Declarations

:

: This study involved animal experiments performed by one of the authors and was approved by the Institutional Animal Ethics Committee of Cape Bio Lab & Research Centre, Tamil Nadu, India, under the ethical code CBLRC/IAEC/03/01-2025.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below